Ozempic review: is it worth it?
Ozempic is semaglutide approved for type 2 diabetes. Often prescribed off-label for weight loss.
A proven diabetes drug, not a weight-loss shortcut
For adults with type 2 diabetes, Ozempic is one of the most well-supported options available: it reliably lowers blood sugar, has shown cardiovascular and kidney benefits in high-risk patients, and produces modest weight loss as a secondary effect. But it is FDA-approved for diabetes (plus cardiovascular and kidney risk reduction in qualifying patients), not for obesity, so using it solely for weight loss is off-label, and people in that situation should ask their doctor about Wegovy, which contains the same molecule at a higher dose and is approved for weight management. Expect real, usually manageable GI side effects and a high list price.
Check PriceFrom $997/mo
Pros
- ✓Strong, well-documented blood-sugar control, lowering A1C by roughly 1 to 2 percentage points in trials
- ✓Reduced the combined rate of major cardiovascular events (heart attack, stroke, CV death) by 26% in high-risk patients in the SUSTAIN-6 trial, driven mainly by fewer strokes
- ✓Newly FDA-approved (January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease in type 2 diabetes with chronic kidney disease, the broadest indication in its class
- ✓Convenient once-weekly injection rather than daily dosing, with modest weight loss as a secondary benefit
- ✓Backed by an extensive, multi-trial clinical evidence base and years of real-world use
Cons
- ✕Frequent gastrointestinal side effects, including nausea, vomiting, and diarrhea, especially when starting or increasing the dose
- ✕Not FDA-approved for weight loss alone, so using it solely to lose weight is off-label and usually not covered by insurance
- ✕High cost, with a list price around $935/month and retail cash prices near $935-$969/month without insurance, and coverage gaps are common
- ✕Carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2; SUSTAIN-6 also reported more diabetic retinopathy complications
- ✕Requires ongoing weekly injections, and benefits (including weight loss and blood-sugar control) tend to reverse if you stop taking it
How it works
Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.
Active ingredient: Semaglutide
Effectiveness
Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.
Side effects
The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.
Cost
Starts at $997/mo from Novo Nordisk.
As of 2026, Ozempic's list price (WAC) is roughly $935 per month, and retail cash prices at major pharmacies run about $935-$969 per month without insurance or discounts. Novo Nordisk's NovoCare direct self-pay program offers cash prices of about $349/month for the 0.25, 0.5, and 1 mg pens and about $499/month for the 2 mg pen, with an introductory offer near $199/month for some new patients on the 0.25 mg and 0.5 mg doses through June 30, 2026. Commercially insured patients with coverage may pay as little as $25/month using the manufacturer savings card, but that lowest pricing is capped (up to $100/month in savings, for a limited number of months) and excludes people with government insurance. Medicare and Medicaid typically cover Ozempic for diabetes (but not for off-label weight loss), and a Patient Assistance Program provides free medication to qualifying low-income, uninsured patients. GoodRx-style coupons usually trim the retail price only modestly. Confirm current pricing and your own coverage before starting.
Is it worth it?
If you have type 2 diabetes, especially with heart or kidney disease, Ozempic is a strong, evidence-backed choice with cardiovascular and renal benefits few diabetes drugs can match. If your only goal is weight loss, Wegovy is the on-label sibling. Either way, plan for GI side effects, weekly injections, and a frank conversation about cost and insurance. Only a licensed clinician can decide whether Ozempic is right for you; this is general information, not medical advice.
Frequently asked questions
Is Ozempic approved for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes, for reducing cardiovascular risk in those with heart disease, and for slowing chronic kidney disease in diabetes, not for weight loss. Its sister drug Wegovy contains the same medication (semaglutide) at a higher dose and is FDA-approved for chronic weight management.
How much weight can you lose on Ozempic?
In type 2 diabetes trials, people lost roughly 6 to 14 lb on average over about 30 to 56 weeks, depending on the dose. Weight loss is a secondary effect of Ozempic, not its primary purpose, and tends to be greater with the higher-dose, weight-loss-specific drug Wegovy. Individual results vary.
What is the difference between Ozempic and Wegovy?
Both contain the same active drug, semaglutide. Ozempic is FDA-approved for type 2 diabetes (plus cardiovascular and kidney risk reduction) and tops out at 2 mg weekly; Wegovy is FDA-approved for weight management and is dosed higher (up to 2.4 mg weekly), generally producing more weight loss.
How long does Ozempic take to work?
Blood-sugar effects begin within the first few weeks, but it typically takes about 4 to 8 weeks at an effective dose (0.5 mg or higher) to see a meaningful A1C improvement. Weight changes usually appear gradually over several months.
What are the most common side effects of Ozempic?
The most common side effects are gastrointestinal: nausea (about 16-20% of patients), vomiting, diarrhea, abdominal pain, and constipation. They are usually worst when starting Ozempic or increasing the dose and often improve over time. Tell your doctor about severe or persistent symptoms.
Who should not take Ozempic?
Avoid Ozempic if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. It is also not for type 1 diabetes. Use caution with a history of pancreatitis, gallbladder disease, or diabetic retinopathy, and discuss pregnancy with your doctor.
How much does Ozempic cost without insurance in 2026?
As of 2026, the list price is about $935 per month, and retail cash prices run roughly $935 to $969 per month. Novo Nordisk's NovoCare self-pay program offers lower cash prices (about $349/month for most pens, $499/month for the 2 mg pen), and commercially insured patients may pay as little as $25/month with the savings card, though that lowest price is capped and time-limited.
What happens if you stop taking Ozempic?
Blood sugar usually rises again and much of any weight lost tends to return, because the drug's appetite and metabolic effects are active only while you take it. Do not stop Ozempic on your own; discuss any changes with your doctor first.
Do you have to take Ozempic forever?
For most people, Ozempic is a long-term therapy. Type 2 diabetes is a chronic condition, and the blood-sugar, weight, and cardiovascular benefits generally persist only while treatment continues. Your doctor can advise on how long you should stay on it.
Sources
- OZEMPIC (semaglutide) injection - Full Prescribing Information — DailyMed (U.S. National Library of Medicine) (2025)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — New England Journal of Medicine (2016)
- FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease — Novo Nordisk / PR Newswire (2025)
- Semaglutide - StatPearls — StatPearls, NCBI Bookshelf (2024)
- Ozempic (semaglutide) injection Savings Offer and Self-Pay Pricing — NovoCare (Novo Nordisk) (2026)